Clinical Trials

List of publications on aHUS  published by aHUS Alliance:
http://www.ahusallianceaction.org/list-of-publications-on-ahus/

December 8, 2013:
New Data Presented at ASH Annual Meeting Enhance Understanding of aHUS to Provide Optimal Care for Patients
Press release here.

November 9, 2013:
Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Press release here.

Feb. 19, 2015:
Omeros Corporation’s Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use - The Company Agrees to Physician Request to Continue Treatment of Patients with aHUS -
Press release here.

July 23, 2015:
FDA Grants “Fast Track” to Omeros’ Complement Inhibitor OMS721 for aHUS
Press release here. 

August 18, 2015:
Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients –
Press release here.

December 2, 2015
Ra Pharmaceuticals Announces Initiation of First-in-Human Clinical Trial of Novel Complement C5 Inhibitor
Press release here

February 24, 2016
Physicians Increasingly Seek Access to OMS721 Compassionate Use Program (OMS721 Requested for Finnish Patient Not  Adequately Responsive to Soliris)
Press release here